Search

Delivery of drugs with controlled temporal profiles is essential for wound treatment and regenerative medicine applications. For example, bacterial infection is a key challenge in the treatment of chronic and deep wounds. Current treatment strategies are based on systemic administration of high doses of antibiotics, which result in side effects and drug resistance. On-demand delivery of drugs with controlled temporal profile is highly desirable. Here, we have developed thermally controllable, antibiotic-releasing nanofibrous sheets. Poly(glycerol sebacate)- poly(caprolactone) (PGS-PCL) blends were electrospun to form elastic polymeric sheets with fiber diameters ranging from 350 to 1100 nm and substrates with a tensile modulus of approximately 4-8 MPa. A bioresorbable metallic heater was patterned directly on the nanofibrous substrate for applying thermal stimulation to release antibiotics on-demand. In vitro studies confirmed the platform's biocompatibility and biodegradability. The released antibiotics were potent against tested bacterial strains. These results may pave the path toward developing electronically controllable wound dressings that can deliver drugs with desired temporal patterns.

Electrospun micro- and nanofibrous poly(glycerol sebacate)-poly(ε-caprolactone) (PGS-PCL) substrates have been extensively used as scaffolds for engineered tissues due to their desirable mechanical properties and their tunable degradability. In this study, we fabricated micro/nanofibrous scaffolds from a PGS-PCL composite using a standard electrospinning approach and then coated them with silver (Ag) using a custom radio frequency (RF) sputtering method. The Ag coating formed an electrically conductive layer around the fibers and decreased the pore size. The thickness of the Ag coating could be controlled, thereby tailoring the conductivity of the substrate. The flexible, stretchable patches formed excellent conformal contact with surrounding tissues and possessed excellent pattern-substrate fidelity. In vitro studies confirmed the platform's biocompatibility and biodegradability. Finally, the potential controlled release of the Ag coating from the composite fibrous scaffolds could be beneficial for many clinical applications.

Herein, the immobilization of α-amylase onto hydroxyapatite (HA) and hydroxyapatite-decorated ZrO 2 (10%wt) (HA-ZrO 2 ) nanocomposite were investigated. The immobilization yield was 69.7% and 84% respectively. The structural differences were characterized using X-Ray diffraction, attenuated total reflectance-Fourier transform infrared spectra, Raman, and scanning electron microscope. After 10 repeated cycles, the residual activity of immobilized α-amylase onto HA and HA-ZrO 2 nanocomposite was 46% and 70%, respectively. The storage stability was recorded to be 27%, 50% and 69% from its initial activity in the case of free and immobilized enzyme onto HA and HA-ZrO 2 nanocomposite, respectively after 8 weeks. The pH-activity profile and temperature revealed pH 6.0 and temperature 50 °C as the optimal values of free α-amylase, while the optimum values for α-amylase on HA and HA-ZrO 2 was shifted to pH 6.5 and 60 °C after immobilization. The immobilized α-amylase onto HA-ZrO 2 showed comparatively higher catalytic activity than the free α-amylase. The Km value after the immobilization process onto HA was 2.1 folds highly than that of the free enzyme. In conclusion, it can be inferred that HA-ZrO 2 is more sustainable and beneficial support for enzyme immobilization and it represents promising supports for different uses of α-amylase in the biomedical applications., Competing Interests: Declaration of competing interest We the undersigned declare that this manuscript is original, has not been published before and is not currently being considered for publication elsewhere. We confirm that the manuscript has been read and approved by all named authors and that there are no other persons who satisfied the criteria for authorship but are not listed, we further confirm that the order of authors listed in the manuscript has been approved by all of us. We declare that we have no conflict of interest., (Copyright © 2020 Elsevier B.V. All rights reserved.)